Aiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti–PD-1 agents.
Aiwu Ruth He, MD, an associate professor of Medicine at Georgetown-Lombardi Comprehensive Cancer Center, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal (GI) and gastric cancers and which patients are most likely to benefit from the antiPD-1 agents.
For patients with upper GI or gastric cancer, the single-agent antiPD-1 therapy nivolumab (Opdivo) is available in the chemotherapy-refractory setting. Patients need to have a combined positive score (CPS) greater than 1 to receive this therapy, He notes, as those patients tend to benefit from anti–PD-1 therapy.
Some clinical trials are also evaluating checkpoint inhibitors in the frontline andsecondlinesetting for patients with upper GI and gastric cancers. Initialdata
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More